CSL Ltd (ASX:CSL)
A$ 278.09 0.46 (0.17%) Market Cap: 134.17 Bil Enterprise Value: 150.72 Bil PE Ratio: 36.59 PB Ratio: 5.23 GF Score: 91/100

CSL Ltd Offers to Acquire 100% of Vifor Pharma Ltd Transcript

Dec 14, 2021 / 07:00AM GMT
Release Date Price: A$297.27
Operator

Thank you for standing by, and welcome to the CSL Investor Briefing.

(Operator Instructions)

I would now like to hand the conference over to Mark Dehring, Head of Investor Relations. Please go ahead.

Mark Dehring
CSL Limited - Head of IR

Good. Thanks, operator, and good evening, ladies and gentlemen. Welcome to CSL's briefing on today's announcement about the tender offer to acquire 100% of Vifor Pharma Ltd. As just mentioned, it's Mark Dehring speaking, and joining me online is Paul Perreault CSL's Chief Executive Officer; Joy Linton, CSL's Chief Financial Officer; and Bill Mezzanotte, CSL's Executive VP, Head of Research and Development and Chief Medical Officer. And Paul will be providing an overview of the transaction highlights. Then Joy will provide some additional detail on the financials. And then, of course, we do have an opportunity for Q&A.

(Operator Instructions) Please note, this briefing is being recorded. And lastly, before we start, I draw your attention to the core statement disclaimer contained in the slide

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot